(S)-ethyl 1-(4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-4-carboxylate | 1444001-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-ethyl 1-(4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-4-carboxylate
• 英文别名: ethyl 1-[4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]piperidine-4-carboxylate
• CAS: 1444001-04-0
• 化学式: C₁₈H₂₅N₃O₄
• 分子量: 347.414
• InChiKey: ZNPRFOCRNPVNSW-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  25.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  85.1
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (S)-ethyl 1-(4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-4-carboxylate 在 水 、 三乙胺 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 45.0h， 生成 (S)-1-(4-(5-((2-aminothiazole-5-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-4-carboxylic acid trifluoroacetate
  参考文献：
  名称：

  Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

  摘要：

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.056
• 作为产物：
  描述：

  哌啶-4-甲酸乙酯 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 一水合肼 作用下， 以 四氢呋喃 、 乙醇 、 二甲基亚砜 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 47.5h， 生成 (S)-ethyl 1-(4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-4-carboxylate
  参考文献：
  名称：

  Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

  摘要：

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.056

文献信息

• Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety
  作者：Uroš Trstenjak、Janez Ilaš、Danijel Kikelj

  DOI：10.1039/c3md00250k

  日期：——

  Replacement of the P4 morpholin-3-one moiety in a selective factor Xa inhibitor rivaroxaban by 2-ethoxycarbonylpiperidine resulted in a dual factor Xa/thrombin inhibitor 24, possessing a Ki of 62 ± 18 nM for factor Xa and a Ki of 353 ± 75 nM for thrombin. Presented rationalization of dual activity provides a good starting point for “designing in” thrombin inhibitory activity to potent factor Xa inhibitor rivaroxaban.

  将选择性因子Xa抑制剂利伐沙班中的P4吗啉-3-酮部分替换为2-乙氧基羰基哌啶，得到了一种双重因子Xa/凝血酶抑制剂24，其对因子Xa的Ki值为62 ± 18 nM，对凝血酶的Ki值为353 ± 75 nM。提出的双重活性合理化为“设计”凝血酶抑制活性到强效因子Xa抑制剂利伐沙班提供了良好的起点。
• Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores
  作者：Uroš Trstenjak、Janez Ilaš、Danijel Kikelj

  DOI：10.1016/j.ejmech.2013.03.056

  日期：2013.6

  Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described. (C) 2013 Elsevier Masson SAS. All rights reserved.